Zobrazeno 1 - 10 of 12 pro vyhledávání: '"Katrin, Holzwarth"'
1
Akademický článek
Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials
Autor: Thomas Bieber, Norito Katoh, Eric L. Simpson, Marjolein de Bruin-Weller, Diamant Thaçi, Antonio Torrelo, Angelina Sontag, Susanne Grond, Maher Issa, Xiaoyu Lu, Tracy Cardillo, Katrin Holzwarth, Jacob P. Thyssen
Publikováno v: Journal of Dermatological Treatment, Vol 34, Iss 1 (2023)
Background Baricitinib, a selective Janus kinase (JAK)1/JAK2 inhibitor, is approved for treatment of moderate-to-severe atopic dermatitis (AD) in adults. Objectives We report integrated baricitinib safety data in patients with up to 3.9-years exposur
Externí odkaz: https://doaj.org/article/ca9ed6e40be942ef9798f73046c71ec1
Zobrazit plný text záznamu
2
Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials
Autor: Brett King, Arash Mostaghimi, Yutaka Shimomura, Abraham Zlotogorski, Gwang-Seong Choi, Ulrike Blume-Peytavi, Thierry Passeron, Katrin Holzwarth, Yves Dutronc, Jill McCollam, Fan Emily Yang, Sarah Stanley, Wen-Shuo Wu, Rodney Sinclair
Publikováno v: British Journal of Dermatology. 188:218-227
Background Baricitinib, an oral, selective, reversible Janus kinase (JAK)1/JAK2 inhibitor, is an approved treatment for adults with severe alopecia areata (AA) in the USA, European Union and Japan. Objectives To report safety data for baricitinib in
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3bacb22708073ac4764585645bafb8fa
https://doi.org/10.1093/bjd/ljac059
Zobrazit plný text záznamu
4
Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials
Autor: Edward Lain, Fabio P. Nunes, Dennis Brinker, Catherine Maari, Maher Issa, Eric L. Simpson, Tracy Cardillo, Katrin Holzwarth, Jonathan I. Silverberg, Brett A. King
Publikováno v: American Journal of Clinical Dermatology
Background Baricitinib, a selective Janus kinase 1/Janus kinase 2 inhibitor, is indicated in the European Union and Japan for the treatment of moderate-to-severe atopic dermatitis (AD) in adults who are candidates for systemic therapy. Objective The
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7be42197ba267ec6e760c1d53e777c73
https://doi.org/10.1007/s40257-021-00602-x
Zobrazit plný text záznamu
5
Two Phase 3 Trials of Baricitinib for Alopecia Areata
Autor: Brett, King, Manabu, Ohyama, Ohsang, Kwon, Abraham, Zlotogorski, Justin, Ko, Natasha A, Mesinkovska, Maria, Hordinsky, Yves, Dutronc, Wen-Shuo, Wu, Jill, McCollam, Chiara, Chiasserini, Guanglei, Yu, Sarah, Stanley, Katrin, Holzwarth, Amy M, DeLozier, Rodney, Sinclair, Matthew, Zirwas
Publikováno v: The New England journal of medicine. 386(18)
Alopecia areata is an autoimmune condition characterized by rapid hair loss in the scalp, eyebrows, and eyelashes, for which treatments are limited. Baricitinib, an oral, selective, reversible inhibitor of Janus kinases 1 and 2, may interrupt cytokin
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56c835e83b3bf5f0047cf3f976d1ff3e
https://pubmed.ncbi.nlm.nih.gov/35507486
Zobrazit plný text záznamu
6
Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials
Autor: T. Bieber, Margaret Gamalo, Fabio P. Nunes, Norito Katoh, Diamant Thaçi, Maher Issa, Kristian Reich, Dennis Brinker, Jamie Weisman, Eric L. Simpson, E. Riedl, Antonio Torrelo, M S de Bruin-Weller, Jacob P. Thyssen, Robert Bissonnette, Katrin Holzwarth, Melinda Gooderham, Jonathan Janes
Publikováno v: Journal of the European Academy of Dermatology and Venereology. 35:476-485
Background Janus kinase (JAK) inhibition is a new mode of action in atopic dermatitis (AD); clarity about drug class safety considerations in the context of AD is important. Baricitinib, an oral, reversible, selective inhibitor of JAK1/JAK2, is in la
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70be05fd68d8b28351af8405ac359cb2
https://doi.org/10.1111/jdv.16948
Zobrazit plný text záznamu
8
Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study
Autor: Manabu Ohyama, Brett A. King, Guanglei Yu, Margaret Gamalo, Yves Dutronc, Jill Shwed McCollam, Justin M. Ko, Emily Edson-Heredia, Katrin Holzwarth, Seth Forman, Natasha Atanaskova Mesinkovska, Jonathan Janes
Publikováno v: Journal of the American Academy of Dermatology. 85(4)
Background There are no treatments approved by the Food and Drug Administration for alopecia areata. Objective To evaluate the efficacy and safety of baricitinib in patients with ≥50% scalp hair loss in a phase 2 study of adults with alopecia areat
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ffac2677b2b47d798de6e90348532fab
https://pubmed.ncbi.nlm.nih.gov/34090959
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje